SG11201900163PA - Macrocycle kinase inhibitors - Google Patents
Macrocycle kinase inhibitorsInfo
- Publication number
- SG11201900163PA SG11201900163PA SG11201900163PA SG11201900163PA SG11201900163PA SG 11201900163P A SG11201900163P A SG 11201900163PA SG 11201900163P A SG11201900163P A SG 11201900163PA SG 11201900163P A SG11201900163P A SG 11201900163PA SG 11201900163P A SG11201900163P A SG 11201900163PA
- Authority
- SG
- Singapore
- Prior art keywords
- ste
- international
- san diego
- center drive
- california
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662367886P | 2016-07-28 | 2016-07-28 | |
| PCT/US2017/044214 WO2018022911A1 (en) | 2016-07-28 | 2017-07-27 | Macrocycle kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201900163PA true SG11201900163PA (en) | 2019-02-27 |
Family
ID=61016718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201900163PA SG11201900163PA (en) | 2016-07-28 | 2017-07-27 | Macrocycle kinase inhibitors |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10689400B2 (es) |
| EP (1) | EP3490564A4 (es) |
| JP (1) | JP2019527230A (es) |
| KR (1) | KR20190034225A (es) |
| CN (1) | CN109715165A (es) |
| AU (1) | AU2017302019A1 (es) |
| BR (1) | BR112019001607A2 (es) |
| CA (1) | CA3031100A1 (es) |
| IL (1) | IL264395A (es) |
| MX (1) | MX2019001125A (es) |
| RU (1) | RU2019105587A (es) |
| SG (1) | SG11201900163PA (es) |
| TW (1) | TW201815799A (es) |
| WO (1) | WO2018022911A1 (es) |
| ZA (1) | ZA201901034B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3636649T3 (fi) | 2014-01-24 | 2024-05-02 | Turning Point Therapeutics Inc | Diaryylimakrosyklejä proteiinikinaasien modulaattoreina |
| US10316044B2 (en) | 2015-07-02 | 2019-06-11 | Tp Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
| RU2728579C2 (ru) | 2015-07-21 | 2020-07-30 | Тёрнинг Поинт Терапьютикс, Инк. | Хиральные диарильные макроциклы и их применение |
| EP3490564A4 (en) | 2016-07-28 | 2020-02-26 | Turning Point Therapeutics, Inc. | MACRO CYCLE Kinase Inhibitors |
| TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| UA126158C2 (uk) | 2017-07-28 | 2022-08-25 | Тьорнінґ Поінт Терапьютикс, Інк. | Макроциклічні сполуки і їх використання |
| CN109516999B (zh) * | 2017-11-01 | 2021-08-17 | 郑州泰基鸿诺医药股份有限公司 | 用作蛋白质激酶调节剂的化合物及其应用 |
| WO2019126121A1 (en) | 2017-12-19 | 2019-06-27 | Tp Therapeutics, Inc. | Macrocyclic compounds for treating disease |
| AU2019241260B2 (en) | 2018-03-28 | 2022-06-16 | Fochon Biosciences, Ltd. | Macrocyclic compounds as TRK kinases inhibitors |
| CA3224949A1 (en) | 2018-07-31 | 2020-02-06 | Loxo Oncology, Inc. | Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide |
| CA3117200A1 (en) | 2018-10-22 | 2020-04-30 | Esker Therapeutics, Inc. | Tyk2 inhibitors and uses thereof |
| US20220235070A1 (en) * | 2019-05-21 | 2022-07-28 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Macrolide derivatives, preparation method and application thereof |
| CN113773335A (zh) * | 2019-06-21 | 2021-12-10 | 成都海博为药业有限公司 | 一种作为蛋白质激酶抑制剂的化合物及其制备方法和用途 |
| WO2021027503A1 (zh) * | 2019-08-12 | 2021-02-18 | 罗欣药业(上海)有限公司 | 三环类化合物、其制备方法、中间体及应用 |
| IL295938A (en) * | 2020-03-02 | 2022-10-01 | Turning Point Therapeutics Inc | Therapeutic uses of macrocyclic compounds |
| CN113754682B (zh) * | 2020-06-04 | 2023-01-06 | 赛诺哈勃药业（成都）有限公司 | 具有大环结构的化合物及其用途 |
| US20240132517A1 (en) * | 2021-02-10 | 2024-04-25 | Goharmony Therapeutics (Shenzhen) Co., Ltd. | Macrocyclic compound, pharmaceutical composition, and use thereof |
| CN113354548A (zh) * | 2021-04-12 | 2021-09-07 | 常熟耐素生物材料科技有限公司 | 一种基于六亚甲基四胺的植物多烯酚醛胺环氧固化剂及其制备方法 |
| CN116063326A (zh) * | 2021-11-02 | 2023-05-05 | 赛诺哈勃药业（成都）有限公司 | 作为蛋白激酶调节剂的含氨基大环化合物 |
| WO2023208244A1 (zh) * | 2022-04-29 | 2023-11-02 | 南京明德新药研发有限公司 | 大环类化合物及其应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ263403A (en) | 1993-03-25 | 1996-10-28 | Upjohn Co | (oxa)cycloalkyl fused indole and benzofuran amines |
| GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| US7517882B2 (en) * | 2006-09-18 | 2009-04-14 | Polaris Group | Protein kinase inhibitors |
| EP2334301B1 (en) | 2008-09-08 | 2018-02-14 | Merck Serono SA | Macrocyclics pyrimidines as aurora kinase inhibitors |
| RS53350B (en) | 2008-09-22 | 2014-10-31 | Array Biopharma, Inc. | SUBSTITUTED COMPOUNDS OF IMIDASO [1,2-B] PYRIDASINE AS INK KINASE INHIBITORS |
| SI3372605T1 (sl) | 2008-10-22 | 2022-03-31 | Array Biopharma, Inc. | Substituirane pirazolo(1,5-a)pirimidinske spojine kot zaviralci TRK-kinaze |
| CN102271515B (zh) | 2008-10-31 | 2014-07-02 | 健泰科生物技术公司 | 吡唑并嘧啶jak抑制剂化合物和方法 |
| EP3521291A1 (en) * | 2010-05-20 | 2019-08-07 | Array Biopharma, Inc. | Macrocyclic compounds as trk kinase inhibitors |
| US8757434B2 (en) * | 2010-07-01 | 2014-06-24 | The Coca-Cola Company | Merchandiser |
| US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
| EP2508607A1 (en) | 2011-04-07 | 2012-10-10 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for liver regeneration and for treatment of liver failure |
| AU2012257513B2 (en) * | 2011-05-19 | 2017-05-11 | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Macrocyclic compounds as protein kinase inhibitors |
| WO2013001310A1 (en) | 2011-06-30 | 2013-01-03 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Macrocyclic compounds and their use as cdk8 inhibitors |
| BR112014003802A2 (pt) | 2011-08-19 | 2017-06-13 | Merck Sharp & Dohme | composto, composto composição farmacêutica, uso de um composto, método para fabricar um composto, e, preparação de um medicamento |
| BR112014007654A8 (pt) * | 2011-09-30 | 2018-06-12 | Ipsen Pharma | Inibidores de lrrk2 quinase macrocíclicos. |
| KR20140078710A (ko) | 2011-09-30 | 2014-06-25 | 온코디자인 에스.에이. | 거대고리 flt3 키나제 억제제 |
| AU2013229173B2 (en) | 2012-03-06 | 2017-06-01 | Pfizer Inc. | Macrocyclic derivatives for the treatment of proliferative diseases |
| JP6418949B2 (ja) | 2012-03-09 | 2018-11-07 | レクシコン ファーマシューティカルズ インコーポレイテッド | イミダゾ［１，２−ｂ］ピリダジン系化合物、それを含む組成物、及びそれらを使用する方法 |
| JP6418950B2 (ja) | 2012-03-09 | 2018-11-07 | レクシコン ファーマシューティカルズ インコーポレイテッド | ピラゾロ［１，５−ａ］ピリミジン系化合物、それを含む組成物、及びそれらを使用する方法 |
| GB201205669D0 (en) | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
| KR20150133765A (ko) * | 2013-03-15 | 2015-11-30 | 온코디자인 에스.에이. | 거대고리 rip2 키나제 억제제 |
| CN104513253A (zh) * | 2013-10-01 | 2015-04-15 | 南京波尔泰药业科技有限公司 | 用于治疗增殖性疾病的大环化合物 |
| FI3636649T3 (fi) | 2014-01-24 | 2024-05-02 | Turning Point Therapeutics Inc | Diaryylimakrosyklejä proteiinikinaasien modulaattoreina |
| US10316044B2 (en) | 2015-07-02 | 2019-06-11 | Tp Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
| BR112018000297A2 (pt) | 2015-07-06 | 2018-09-04 | Tp Therapeutics Inc | polimorfo de macrociclo de diarila |
| RU2728579C2 (ru) | 2015-07-21 | 2020-07-30 | Тёрнинг Поинт Терапьютикс, Инк. | Хиральные диарильные макроциклы и их применение |
| EP3490564A4 (en) | 2016-07-28 | 2020-02-26 | Turning Point Therapeutics, Inc. | MACRO CYCLE Kinase Inhibitors |
| TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| UA126158C2 (uk) | 2017-07-28 | 2022-08-25 | Тьорнінґ Поінт Терапьютикс, Інк. | Макроциклічні сполуки і їх використання |
-
2017
- 2017-07-27 EP EP17835284.5A patent/EP3490564A4/en active Pending
- 2017-07-27 US US16/320,589 patent/US10689400B2/en active Active
- 2017-07-27 RU RU2019105587A patent/RU2019105587A/ru not_active Application Discontinuation
- 2017-07-27 KR KR1020197003927A patent/KR20190034225A/ko not_active Application Discontinuation
- 2017-07-27 WO PCT/US2017/044214 patent/WO2018022911A1/en unknown
- 2017-07-27 SG SG11201900163PA patent/SG11201900163PA/en unknown
- 2017-07-27 MX MX2019001125A patent/MX2019001125A/es unknown
- 2017-07-27 AU AU2017302019A patent/AU2017302019A1/en not_active Abandoned
- 2017-07-27 JP JP2019504675A patent/JP2019527230A/ja active Pending
- 2017-07-27 CN CN201780056515.5A patent/CN109715165A/zh active Pending
- 2017-07-27 BR BR112019001607-4A patent/BR112019001607A2/pt not_active Application Discontinuation
- 2017-07-27 CA CA3031100A patent/CA3031100A1/en active Pending
- 2017-07-27 TW TW106125249A patent/TW201815799A/zh unknown
-
2019
- 2019-01-22 IL IL264395A patent/IL264395A/en unknown
- 2019-02-18 ZA ZA2019/01034A patent/ZA201901034B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3031100A1 (en) | 2018-02-01 |
| AU2017302019A1 (en) | 2019-02-07 |
| US20190169208A1 (en) | 2019-06-06 |
| IL264395A (en) | 2019-02-28 |
| RU2019105587A (ru) | 2020-08-28 |
| KR20190034225A (ko) | 2019-04-01 |
| JP2019527230A (ja) | 2019-09-26 |
| TW201815799A (zh) | 2018-05-01 |
| EP3490564A4 (en) | 2020-02-26 |
| RU2019105587A3 (es) | 2020-11-18 |
| WO2018022911A1 (en) | 2018-02-01 |
| US10689400B2 (en) | 2020-06-23 |
| ZA201901034B (en) | 2021-06-30 |
| BR112019001607A2 (pt) | 2019-04-30 |
| EP3490564A1 (en) | 2019-06-05 |
| MX2019001125A (es) | 2019-06-12 |
| CN109715165A (zh) | 2019-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201808138YA (en) | Substituted indole derivatives as dengue viral replication inhibitors | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201902531QA (en) | Liquid pharmaceutical composition | |
| SG11201808221QA (en) | 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201901228QA (en) | Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer |